Alterity Therapeutics Ltd ADR (ATHE) Stock Price, Quote & News - Mboum

Company Profile

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clin...

Industry: Biotechnology

Sector: Healthcare

Phone: 61 3 9349 4906

Fax: 61 3 9349 4906

Website: alteritytherapeutics.com

Address:

350 Collins Street, Suite 4 Level 14, Melbourne, Australia

stckmuncher Apr. 16 at 9:05 PM

$ATHE $20 Target by July!!!!!!! FUCK YOU SHORTS…EAT MY NON-BLEACHED ASS.

0 · Reply

stckmuncher Apr. 16 at 9:05 PM

$ATHE GET READY TO GET BLOWN……………..AWAY! 😂🙏🏻🤠

0 · Reply

tommy_john Apr. 16 at 8:15 PM

$ATHE this little guy should approach double digits

0 · Reply

stckmuncher Apr. 16 at 5:40 PM

$ATHE 20X here we come 😀.

0 · Reply

TwongStocks Apr. 16 at 11:39 AM

$ATHE Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting https://www.globenewswire.com/news-release/2026/04/16/3275212/0/en/Alterity-Therapeutics-Announces-Late-Breaker-Oral-Presentation-at-the-American-Academy-of-Neurology-Annual-Meeting.html Oral Presentation --> "ATH434 Demonstrates Disease-Modifying Signal in Multiple System Atrophy Using the MuSyCA Composite Scale"

0 · Reply

CARTE_BLANCHE_DEVEREAUX Apr. 15 at 8:35 PM

$SLS $ATHE $CING $PYPD Lol. @PeterRaslow sucks at facts and trading.

1 · Reply

Dingo2 Apr. 15 at 4:12 PM

$ATHE can you imagine what this would do with a tiny bit of the $BIRD volume? That would be fun 😎

0 · Reply

RocketMan88 Apr. 13 at 5:29 PM

$ATHE I have sent dozens of letters to Nancy Pelosi’s office about this stock opportunity. It is now inevitable that this stock blows up. All we need is the greatest stock trader of all time in our corner to break this thing out.

1 · Reply

stckmuncher Apr. 12 at 5:32 PM

$ATHE What’s going on with Phase III news?

1 · Reply

RocketMan88 Apr. 10 at 6:52 PM

0 · Reply

Latest News on ATHE

Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program

Mar 30, 2026, 7:25 AM EDT - 17 days ago

Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program

Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit

Mar 9, 2026, 7:25 AM EDT - 5 weeks ago

Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit

Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments

Mar 2, 2026, 7:25 AM EST - 6 weeks ago

Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments

Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

Jan 30, 2026, 7:25 AM EST - 2 months ago

Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference

Nov 12, 2025, 7:25 AM EST - 5 months ago

Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference

Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report

Oct 31, 2025, 7:25 AM EDT - 5 months ago

Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Oct 9, 2025, 7:25 AM EDT - 6 months ago

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Oct 2, 2025, 7:35 AM EDT - 7 months ago

Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Alterity Therapeutics Raises A$20.0 million in Strategic Placement

Sep 8, 2025, 7:35 AM EDT - 7 months ago

Alterity Therapeutics Raises A$20.0 million in Strategic Placement

Alterity Therapeutics to Present at the Biotech Showcase

Sep 2, 2025, 7:25 AM EDT - 8 months ago

Alterity Therapeutics to Present at the Biotech Showcase

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

Jul 30, 2025, 7:25 AM EDT - 9 months ago

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

Jul 28, 2025, 7:25 AM EDT - 9 months ago

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study

Jul 24, 2025, 7:25 AM EDT - 9 months ago

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study

Alterity Therapeutics to Provide Corporate Update in Fireside Chat

Jun 23, 2025, 7:25 AM EDT - 10 months ago

Alterity Therapeutics to Provide Corporate Update in Fireside Chat

Alterity Therapeutics Prominently Featured at the International MSA Congress

May 12, 2025, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Prominently Featured at the International MSA Congress

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

May 7, 2025, 8:16 AM EDT - 1 year ago

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

May 5, 2025, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

Apr 30, 2025, 7:35 AM EDT - 1 year ago

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

Apr 28, 2025, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

Apr 10, 2025, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

Mar 27, 2025, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

Alterity Therapeutics Raises A$40.0 million in Placement

Feb 10, 2025, 7:25 AM EST - 1 year ago

Alterity Therapeutics Raises A$40.0 million in Placement

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

Jan 30, 2025, 7:35 AM EST - 1 year ago

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

Jan 24, 2025, 7:35 AM EST - 1 year ago

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

Jan 9, 2025, 7:25 AM EST - 1 year ago

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

Dec 4, 2024, 7:35 AM EST - 1 year ago

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

Nov 19, 2024, 7:25 AM EST - 1 year ago

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Nov 12, 2024, 7:35 AM EST - 1 year ago

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Nov 6, 2024, 7:35 AM EST - 1 year ago

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

Oct 31, 2024, 7:35 AM EDT - 1 year ago

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

Oct 14, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

Oct 11, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

Oct 2, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

Sep 30, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Sep 23, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

Jul 31, 2024, 7:35 AM EDT - 1 year ago

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

Alterity Therapeutics to Present at MST Financial Webinar

Jul 24, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics to Present at MST Financial Webinar

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Jul 17, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Jul 17, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences' Webinar

Jun 12, 2024, 7:22 PM EDT - 2 years ago

Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences' Webinar

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

May 29, 2024, 7:21 PM EDT - 2 years ago

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

May 8, 2024, 7:25 AM EDT - 2 years ago

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report

Apr 30, 2024, 7:25 AM EDT - 2 years ago

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia

Apr 29, 2024, 7:25 AM EDT - 2 years ago

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia

Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

Apr 17, 2024, 7:25 AM EDT - 2 years ago

Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

Apr 10, 2024, 7:25 AM EDT - 2 years ago

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund

Mar 26, 2024, 10:25 AM EDT - 2 years ago

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

Feb 20, 2024, 10:25 AM EST - 2 years ago

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

Feb 6, 2024, 7:25 AM EST - 2 years ago

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

Jan 29, 2024, 7:24 AM EST - 2 years ago

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

stckmuncher Apr. 16 at 9:05 PM

$ATHE $20 Target by July!!!!!!! FUCK YOU SHORTS…EAT MY NON-BLEACHED ASS.

0 · Reply

stckmuncher Apr. 16 at 9:05 PM

$ATHE GET READY TO GET BLOWN……………..AWAY! 😂🙏🏻🤠

0 · Reply

tommy_john Apr. 16 at 8:15 PM

$ATHE this little guy should approach double digits

0 · Reply

stckmuncher Apr. 16 at 5:40 PM

$ATHE 20X here we come 😀.

0 · Reply

TwongStocks Apr. 16 at 11:39 AM

$ATHE Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting https://www.globenewswire.com/news-release/2026/04/16/3275212/0/en/Alterity-Therapeutics-Announces-Late-Breaker-Oral-Presentation-at-the-American-Academy-of-Neurology-Annual-Meeting.html Oral Presentation --> "ATH434 Demonstrates Disease-Modifying Signal in Multiple System Atrophy Using the MuSyCA Composite Scale"

0 · Reply

CARTE_BLANCHE_DEVEREAUX Apr. 15 at 8:35 PM

$SLS $ATHE $CING $PYPD Lol. @PeterRaslow sucks at facts and trading.

1 · Reply

Dingo2 Apr. 15 at 4:12 PM

$ATHE can you imagine what this would do with a tiny bit of the $BIRD volume? That would be fun 😎

0 · Reply

RocketMan88 Apr. 13 at 5:29 PM

$ATHE I have sent dozens of letters to Nancy Pelosi’s office about this stock opportunity. It is now inevitable that this stock blows up. All we need is the greatest stock trader of all time in our corner to break this thing out.

1 · Reply

stckmuncher Apr. 12 at 5:32 PM

$ATHE What’s going on with Phase III news?

1 · Reply

RocketMan88 Apr. 10 at 6:52 PM

0 · Reply

stckmuncher Apr. 10 at 5:13 PM

$ATHE Need to keep pushing or GTFO!

0 · Reply

GA09 Apr. 9 at 4:59 PM

$ATHE Nice base developing at current levels. EO2 meeting with FDA (mid-2026) and on-going discussions with potential partners (investors and big pharma) and Phase 3 trial design.

0 · Reply

stckmuncher Apr. 9 at 12:04 PM

$ATHE LFG!!!!!!!!!!!!

0 · Reply

Double__Down Apr. 7 at 9:53 PM

$ATHE $LOW & $TEADY

0 · Reply

Dingo2 Apr. 7 at 4:03 PM

$ATHE quiet... ;)

0 · Reply

stckmuncher Apr. 7 at 1:46 PM

$ATHE CLIMB YOU BITCH

0 · Reply

stckmuncher Apr. 6 at 2:25 AM

$ATHE GET READY FOLKS!

0 · Reply

ArloPalaceTrades Mar. 31 at 4:23 AM

$ATHE phase 3 news , im not selling

1 · Reply

DARKP00L Mar. 30 at 9:31 PM

0 · Reply

stckmuncher Mar. 30 at 8:42 PM

$ATHE GLORY COMING SOON!

0 · Reply

topstockalerts Mar. 30 at 5:26 PM

$ATHE this is the type that leaves people waiting on the sidelines

0 · Reply

LewisDaKat Mar. 30 at 5:00 PM

$ATHE Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program https://marketwirenews.com/stock/athe/news/alterity-therapeutics-receives-positive-fda-feedback-7625092929561354.html?utm_source=stocktwits

0 · Reply